A novel human interleukin-24 peptide created by
computer-guided design contributes to suppression of proliferation in esophageal squamous cell carcinoma Eca-109 cells

Ma,Qunfeng; Deng,Xuefeng; Jin,Bangming; Zhang,Yao; Luo,Dan; Song,Heyu; Wang,Pengkun; Zhang,Chi; Li,Xue; Shi,Yinan; Liu,Yan; Chen,Zhinan; Wang,Ziling; Jiang,Hong

doi:10.3892/or.2014.3589

A novel human interleukin-24 peptide created by computer-guided design contributes to suppression of proliferation in esophageal squamous cell carcinoma Eca-109 cells

Authors:
- Qunfeng Ma
- Xuefeng Deng
- Bangming Jin
- Yao Zhang
- Dan Luo
- Heyu Song
- Pengkun Wang
- Chi Zhang
- Xue Li
- Yinan Shi
- Yan Liu
- Zhinan Chen
- Ziling Wang
- Hong Jiang
View Affiliations

Affiliations: Department of Thoracic Surgery, Affiliated Hospital of the Academy of Military Medical Sciences, Fengtai, Beijing 100071, P.R. China, College of Life Science and Bioengineering, School of Science, Beijing Jiaotong University, Haidian, Beijing 100044, P.R. China, College of Life Science, Southwest University, Beibei, Chongqing 400715, P.R. China, Cell Engineering Research Center, The Fourth Military Medical University, Xicheng, Xi'an, Shaanxi 710032, P.R. China
Published online on: November 4, 2014 https://doi.org/10.3892/or.2014.3589
Pages: 193-200

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Based on the three-dimensional modeling structure of human interleukin-24 (hIL-24) and its most likely active position predicted by solvent accessibility and apparent electrostatic properties, a novel hIL-24 peptide M1 was created by computer-guided molecular design. The cytotoxicity and cell selectivity of M1 were examined in three human carcinoma cell lines and one normal human embryo lung fibroblast cell line (HEL). MTT assay showed that M1 induced growth arrest in two IL-20 receptor complex-positive cancer cell lines (the esophageal squamous cell carcinoma cell line Eca-109 and the melanoma cell line A375), and antibodies against IL-24 or IL-20 receptor complexes significantly neutralized the inhibitory activity. Moreover, M1 had almost no cytotoxicity on the lung cancer A549 cell line, which lacks a full complement of the IL-20 receptor complexes, or on HEL cells that express the IL-20 receptor complexes. These findings demonstrate that M1 could act as an excellent candidate for the induction of growth arrest on receptor complex-positive cancer cells. In summary, the M1 peptide may represent a novel anticancer agent for esophageal squamous cell carcinoma therapy due to its cancer cell selectivity and its relatively low cytotoxicity to normal cells.

View Figures

View References

1	Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI
2	Janet P, Whitney S, Fang X, et al: Rational design of shepherdin, a novel anticancer agent. Cancer Cell. 7:457–468. 2005. View Article : Google Scholar
3	Jiang H, Lin JJ, Su ZZ, et al: Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene. 11:2477–2286. 1995.PubMed/NCBI
4	Gupta P, Su ZZ, Lebedeva IV, et al: mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther. 111:596–628. 2006. View Article : Google Scholar : PubMed/NCBI
5	Mhashilkar AM, Schrock RD, Hindi M, et al: Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol Med. 7:271–282. 2001.PubMed/NCBI
6	Dent P, Yacoub A, Hamed HA, et al: MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anticancer Drugs. 21:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
7	Caudell EG, Mumm JB, Poindexter N, et al: The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 168:6041–6046. 2002. View Article : Google Scholar : PubMed/NCBI
8	Mumm JB, Ekmekcioglu S, Poindexter NJ, et al: Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes. J Interferon Cytokine Res. 26:877–886. 2006. View Article : Google Scholar
9	Su ZZ, Lebedeva IV, Sarkar D, et al: Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene. 22:1164–1180. 2003. View Article : Google Scholar : PubMed/NCBI
10	Su Z, Emdad L, Sauane M, et al: Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene. 24:7552–7566. 2005. View Article : Google Scholar : PubMed/NCBI
11	Yacoub A, Liu R, Park MA, et al: Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Mol Pharmacol. 77:298–310. 2010. View Article : Google Scholar :
12	Lebedeva IV, Washington I, Sarkar D, et al: Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas. Proc Natl Acad Sci USA. 104:3484–3489. 2007. View Article : Google Scholar : PubMed/NCBI
13	Bocangel D, Zheng M, Mhashilkar A, et al: Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2⁺ breast cancer cells. Cancer Gene Ther. 13:958–968. 2006. View Article : Google Scholar : PubMed/NCBI
14	Su Z, Lebedeva IV, Gopalkrishnan RV, et al: A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA. 98:10332–10337. 2001. View Article : Google Scholar : PubMed/NCBI
15	Lebedeva IV, Su ZZ, Sarkar D, et al: Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer Res. 63:8138–8144. 2003.PubMed/NCBI
16	Zerbini LF, Czibere A, Wang Y, et al: A novel pathway involving melanoma differentiation associated gene-7/interleukin-24 mediates nonsteroidal anti-inflammatory drug-induced apoptosis and growth arrest of cancer cells. Cancer Res. 66:11922–11931. 2006. View Article : Google Scholar : PubMed/NCBI
17	Chada S, Mhashilkar AM, Liu Y, et al: mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members. Cancer Gene Ther. 13:490–502. 2006. View Article : Google Scholar
18	Zerbini LF, Tamura RE, Correa RG, et al: Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy. PLoS One. 6:e242852011. View Article : Google Scholar
19	Fisher PB: Is mda-7/IL-24 a ‘magic bullet’ for cancer? Cancer Res. 65:10128–10138. 2005. View Article : Google Scholar : PubMed/NCBI
20	Dong CY, Zhang F, Duan YJ, et al: mda-7/IL-24 inhibits the proliferation of hematopoietic malignancies in vitro and in vivo. Exp Hematol. 36:938–946. 2008. View Article : Google Scholar : PubMed/NCBI
21	Saeki T, Mhashilkar A, Swanson X, et al: Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene. 21:4558–4566. 2002. View Article : Google Scholar : PubMed/NCBI
22	Tamai H, Miyake K, Yamaguchi H, et al: AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice. Blood. 11:64–71. 2012. View Article : Google Scholar
23	Pataer A, Hu W, Xiaolin L, et al: Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing. Mol Cancer Ther. 7:2528–2535. 2008. View Article : Google Scholar : PubMed/NCBI
24	Sauane M, Su ZZ, Gupta P, et al: Autocrine regulation of mda-7/ IL-24 mediates cancer-specific apoptosis. Proc Natl Acad Sci USA. 105:9763–9768. 2008. View Article : Google Scholar
25	Margue C and Kreis S: IL-24: physiological and supraphysiological effects on normal and malignant cells. Curr Med Chem. 17:3318–3326. 2010. View Article : Google Scholar : PubMed/NCBI
26	Dash R, Bhutia SK, Azab B, et al: mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev. 21:381–391. 2010. View Article : Google Scholar : PubMed/NCBI
27	Zheng M, Bocangel D, Ramesh R, et al: Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O⁶-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther. 7:3842–3851. 2008. View Article : Google Scholar : PubMed/NCBI
28	Gupta P, Walter MR, Su ZZ, et al: BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis. Cancer Res. 66:8182–8191. 2006. View Article : Google Scholar : PubMed/NCBI
29	Gupta P, Emdad L, Lebedeva IV, et al: Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. J Cell Physiol. 215:827–836. 2008. View Article : Google Scholar : PubMed/NCBI
30	Rosal R, Brandt-Rauf P, Pincus MR, et al: The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis. Adv Drug Deliv Rev. 57:653–660. 2005. View Article : Google Scholar : PubMed/NCBI
31	Böttger A, Böttger V, Sparks A, et al: Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol. 7:860–869. 1997. View Article : Google Scholar
32	Tong AW, Nemunaitis J, Su D, et al: Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 11:160–172. 2005. View Article : Google Scholar
33	Cunningham CC, Chada S, Merritt JA, et al: Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther. 11:149–159. 2005. View Article : Google Scholar
34	Dent P, Yacoub A, Hamed HA, et al: The development of MDA-7/ IL-24 as a cancer therapeutic. Pharmacol Ther. 128:375–384. 2010. View Article : Google Scholar : PubMed/NCBI
35	Sauane M, Gopalkrishnan RV, Sarkar D, et al: MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev. 14:35–51. 2003. View Article : Google Scholar
36	Chada S, Sutton RB, Ekmekcioglu S, et al: MDA-7/IL-24 is a unique cytokine - tumor suppressor in the IL-10 family. Int Immunopharmacol. 4:649–667. 2004. View Article : Google Scholar : PubMed/NCBI
37	Kotenko SV: The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev. 13:223–240. 2002. View Article : Google Scholar : PubMed/NCBI
38	Lebedeva IV, Emdad L, Su ZZ, et al: mda-7/IL-24, novel anticancer cytokine: Focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol. 31:985–1007. 2007.PubMed/NCBI
39	Chada S, Mhashilkar AM, Ramesh R, et al: Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther. 10:1085–1095. 2004. View Article : Google Scholar : PubMed/NCBI